Katalog der Deutschen Nationalbibliothek

Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cells

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell–type diffuse large B-cell lymphoma

VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma

Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease

Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Diffus großzelliges B-Zell-Lymphom : Informationen für Patienten

USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B‐cell lymphoma

Die Bedeutung von SUMOyliertem HSP90 bei hämatologischen Neoplasien und soliden Tumoren

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen

Therapiefortschritte bei aggressiven Lymphomen

Therapiefortschritte bei aggressiven Lymphomen

Proinflammatory Progranulin Antibodies in Inflammatory Bowel Diseases

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

Correction: MHC‐peptide‐specific antibodies reveal inefficient presentation of an HLA‐A*0201‐restricted, Melan‐A‐derived peptide after active intracellular processing

Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS

Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer

Serological immune response to cancer testis antigens in patients with pancreatic cancer

Pathophysiologie, Pathobiochemie : mit 112 Tabellen

Fisiopatología y bioquímica : con 112 tablas

Pathophysiologie - Pathobiochemie : mit 112 Tabellen

Enrichment polymerase chain reaction for the detection of Ki-ras mutations: relevance of Taq polymerase error rate, initial DNA copy number, and reaction conditions on the emergence of false-positive mutant bands

Onkologische Therapie : Leitlinien und Schemata zur Diagnostik, Therapie und Nachsorge

Neue Aspekte für die Chemotherapie von Malignomen : Symposium Berlin, 19. März 1992

Hämoblastosen : 26 Tabellen

Serologische Analyse von Oberflächenantigenen menschlicher Neoplasien

Der Einfluss einer Barorezeptorenreizung auf den Reizerfolg einer elektrischen Reizung der "defence area" des Hypothalamus